Vanda Pharmaceuticals — Patent Portfolio
1 drug with active patents · 63 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Verdict Vanda Pharmaceuticals' patent portfolio is highly vulnerable, with 81% average vulnerability score, and faces significant revenue risk in 2028 with 1 drug losing exclusivity, including milsaperidone.
Portfolio overview Vanda Pharmaceuticals has a total of 2 drugs in its portfolio, with 1 of them having patents. The company holds 63 active US patents, with no expired patents. The average vulnerability score of its patents is 81, indicating a high level of vulnerability. Out of the total patents, none are considered ironclad, while all 63 are vulnerable.
Cliff calendar 5 drugs lose exclusivity in 2028 including milsaperidone. This year will be a significant cliff for the company, with a substantial loss of exclusivity.
Most exposed drugs Milsaperidone is the top drug facing near-term loss of exclusivity, with an earliest active patent expiry date of 2028-03-28, an average vulnerability score of 81, and no annual revenue data available. This drug is the only one in the portfolio with a significant patent portfolio, consisting of 63 patents.
Biologic exclusivity Vanda Pharmaceuticals does not have any biologics in its portfolio.
Strategic implications The company faces significant revenue risk in the next 5 years, with no revenue at risk quantified. To mitigate this risk, the company may consider lifecycle moves such as subQ switches, label extensions, or combination filings to maintain market share and revenue.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
milsaperidone (Milsaperidone)
Cliff 2028 · 2y-
US10570453
Vuln 88
2028-03-28
This patent protects a method for predicting a predisposition to QT prolongation and determining whether a compound, such as Milsaperidone, can induce it.
-
US10570453
Vuln 88
2028-03-28
This patent protects a method for predicting a predisposition to QT prolongation and determining whether a compound, such as Milsaperidone, can induce it.
-
US10570453
Vuln 88
2028-03-28
This patent protects a method for predicting a predisposition to QT prolongation and determining whether a compound, such as Milsaperidone, can induce it.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Method of Use 63 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track Vanda Pharmaceuticals's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export